Biotech firm launches new identity as it ‘builds critical mass’
An Alderley Park-based biotech organisation is broadening its focus and "building critical mass" as it develops new drugs and a new pipeline of opportunities to fight infectious diseases.
It has unveiled a new identity with The AMR Centre now to be known as Infex Therapeutics.
The organisation, which focused on Antimicrobial Resistance (AMR), is taking its proven drug development model and its expertise and putting them to work in the wider infectious disease sector.
Infex is a UK leader in tackling the health crisis around t... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
